<DOC>
	<DOCNO>NCT02826759</DOCNO>
	<brief_summary>This study design compare serum sphingolipidomic analyse healthy , pre-diabetic diabetic subject . age , sex BMI match among three group . As ceramide , sphingosine , sphingosine-1-phosphate sphinganine involve inflammation , immunity cancer , investigator propose hypothesis sphingosine-1-phosphate sphingolipids may associate progress type 2 diabetes . sphingolipids may biomarker diabetes .</brief_summary>
	<brief_title>Serum Sphingolipidomic Analyses Healthy , Diabetic Prediabetic Subjects</brief_title>
	<detailed_description>The first purpose study determine whether serum sphingolipid metabolite associate significantly weight among type 2 diabetes . 60 patient diagnose type 2 diabetes recruit . The serum concentration sphingolipid metabolites 20 type 2 diabetic patient obesity compare age- sex-matched series 40 type 2 patient without obesity . The second purpose study determine whether serum sphingolipid metabolite associate significantly process severity type 2 diabetes . The serum concentration sphingolipid metabolites 20 subject type 2 diabetes compare age- , sex- BMI-matched series healthy pre-diabetic subject . Investigators speculate serum concentration sphingolipid metabolite positively related progression diabetes . In order discover serum sphingolipid metabolite correlate progression diabetes , detailed information HbA1c , duration diabetes history insulin resistance define homeostatic model assessment ( HOMA-IR ) analyse . These three parameter may affect serum concentration sphingolipid metabolite .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>clinical diagnosis diabetes mellitus , type 2 clinical diagnosis prediabetic status old 18 young 90 yearsold clinical diagnosis insulinresistance clinical diagnosis newly onset diabetes mellitus , type 2 willing participate trial sign consent form cardiovascular disease ( myocardial infarction , heart failure , cerebrovascular accident ) miss information BMI sever liver , kidney dysfunction sever pancreatitis receive pancreatectomy medication hormone , immunosuppressive therapy drug may affect bioactivity concentration sphingolipids ( e.g . asprin ) patient pregnancy sever systematic disease include carcinoma , mental disorder , sever anemia et al .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>sphingolipid</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>biomarker</keyword>
	<keyword>obesity</keyword>
	<keyword>insulin resistance</keyword>
</DOC>